Honz Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Honz Pharmaceutical's earnings have been declining at an average annual rate of -30.1%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 11.5% per year.
Key information
-30.1%
Earnings growth rate
-30.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -11.5% |
| Return on equity | -4.2% |
| Net Margin | -7.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Honz Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 670 | -50 | 381 | 19 |
| 31 Dec 23 | 740 | 12 | 353 | 19 |
| 30 Sep 23 | 638 | -98 | 362 | 31 |
| 30 Jun 23 | 640 | -84 | 339 | 29 |
| 31 Mar 23 | 600 | -126 | 340 | 28 |
| 31 Dec 22 | 536 | -188 | 374 | 28 |
| 30 Sep 22 | 600 | -57 | 320 | 12 |
| 30 Jun 22 | 642 | -19 | 364 | 13 |
| 31 Mar 22 | 760 | -5 | 397 | 13 |
| 01 Jan 22 | 837 | 11 | 398 | 15 |
| 30 Sep 21 | 876 | -34 | 426 | 19 |
| 30 Jun 21 | 934 | -56 | 409 | 17 |
| 31 Mar 21 | 937 | -9 | 388 | 17 |
| 31 Dec 20 | 922 | 9 | 377 | 17 |
| 30 Sep 20 | 877 | -26 | 402 | 19 |
| 30 Jun 20 | 897 | -25 | 403 | 19 |
| 31 Mar 20 | 913 | -65 | 446 | 18 |
| 31 Dec 19 | 1,008 | -26 | 443 | 17 |
| 30 Sep 19 | 1,008 | -30 | 424 | 14 |
| 30 Jun 19 | 1,131 | -16 | 457 | 15 |
| 31 Mar 19 | 961 | 15 | 349 | 17 |
| 31 Dec 18 | 883 | 13 | 324 | 17 |
| 30 Sep 18 | 972 | 60 | 328 | 16 |
| 30 Jun 18 | 710 | 60 | 220 | 18 |
| 31 Mar 18 | 743 | 66 | 231 | 15 |
| 31 Dec 17 | 668 | 56 | 212 | 9 |
| 30 Sep 17 | 471 | 55 | 147 | 7 |
| 30 Jun 17 | 463 | 54 | 155 | 0 |
| 31 Mar 17 | 460 | 43 | 154 | 0 |
| 31 Dec 16 | 471 | 46 | 153 | 0 |
| 30 Sep 16 | 501 | 70 | 134 | 0 |
| 30 Jun 16 | 512 | 73 | 146 | 0 |
| 31 Mar 16 | 488 | 93 | 137 | 0 |
| 31 Dec 15 | 410 | 68 | 143 | 0 |
| 30 Sep 15 | 366 | 57 | 160 | 0 |
| 30 Jun 15 | 370 | 58 | 159 | 0 |
| 31 Mar 15 | 364 | 45 | 162 | 0 |
| 31 Dec 14 | 409 | 62 | 161 | 0 |
| 30 Sep 14 | 372 | 31 | 153 | 0 |
| 30 Jun 14 | 338 | 21 | 143 | 0 |
| 31 Mar 14 | 334 | 19 | 141 | 0 |
| 31 Dec 13 | 309 | 15 | 138 | 0 |
| 30 Sep 13 | 313 | 26 | 147 | 0 |
| 30 Jun 13 | 329 | 34 | 153 | 0 |
Quality Earnings: 300086 is currently unprofitable.
Growing Profit Margin: 300086 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300086 is unprofitable, and losses have increased over the past 5 years at a rate of 30.1% per year.
Accelerating Growth: Unable to compare 300086's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300086 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 300086 has a negative Return on Equity (-4.22%), as it is currently unprofitable.